Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States

被引：0
|
作者：
Holly Guy
Vicki Laskier
Mark Fisher
W. Richey Neuman
Iwona Bucior
Steven Deitelzweig
Alexander T. Cohen
机构：
[1] FIECON Ltd,
[2] Portola Pharmaceuticals,undefined
[3] Inc,undefined
[4] Ochsner Clinic Foundation and The University of Queensland School of Medicine,undefined
[5] Ochsner Clinical School,undefined
[6] Guy’s and St,undefined
[7] Thomas’ Hospitals,undefined
来源：
PharmacoEconomics | 2019年 / 37卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：701 / 714
页数：13
相关论文
共 50 条
  • [1] Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States
    Guy, Holly
    Laskier, Vicki
    Fisher, Mark
    Neuman, W. Richey
    Bucior, Iwona
    Deitelzweig, Steven
    Cohen, Alexander T.
    [J]. PHARMACOECONOMICS, 2019, 37 (05) : 701 - 714
  • [2] COST-EFFECTIVENESS OF BETRIXABAN COMPARED WITH ENOXAPARIN OR FONDAPARINUX FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HOSPITALISED ACUTE MEDICALLY ILL PATIENTS IN THE UNITED KINGDOM
    Laskier, V
    Guy, H.
    Fisher, M.
    Neuman, W. R.
    Bucior, I
    Deitelzweig, S. B.
    Cohen, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S106 - S107
  • [3] Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom
    Guy, Holly
    Laskier, Vicki
    Fisher, Mark
    Bucior, Iwona
    Deitelzweig, Steven
    Cohen, Alexander T.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (03) : 259 - 267
  • [4] The cost-effectiveness and cost-utility analysis of the use of enoxaparin compared with heparin for venous thromboembolism prophylaxis in medical inpatients in Iran
    Mohammadreza Amirsadri
    Sarah Mousavi
    Ali Karimipour
    [J]. DARU Journal of Pharmaceutical Sciences, 2019, 27 : 627 - 634
  • [5] The cost-effectiveness and cost-utility analysis of the use of enoxaparin compared with heparin for venous thromboembolism prophylaxis in medical inpatients in Iran
    Amirsadri, Mohammadreza
    Mousavi, Sarah
    Karimipour, Ali
    [J]. DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 27 (02) : 627 - 634
  • [6] Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery
    Sullivan, SD
    Kwong, L
    Nutescu, E
    [J]. VALUE IN HEALTH, 2006, 9 (02) : 68 - 76
  • [7] Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing major orthopedic surgery.
    Sullivan, SD
    Davidson, BL
    Kahn, SR
    Muntz, JE
    Oster, G
    Raskob, GE
    [J]. BLOOD, 2002, 100 (11) : 871A - 871A
  • [8] Cost-effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden
    Jonas Lundkvist
    David Bergqvist
    Bengt Jönsson
    [J]. The European Journal of Health Economics, formerly: HEPAC , 2003, 4 (4): : 254 - 262
  • [9] COST-EFFECTIVENESS OF PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
    POWLEY, JM
    [J]. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1981, 74 (07) : 555 - 555
  • [10] COST-EFFECTIVENESS OF PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
    DAVIES, GC
    SALZMAN, EW
    [J]. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1981, 74 (03) : 177 - 180
12345